Delamanid- A ray of hope for drug resistant tuberculosis

---

Review Article

Author Details : Mohammad Atif, Mohd Maroof, Sankalp Yadav

Volume : 2, Issue : 3, Year : 2017

Article Page : 66-68

Suggest article by email

Get Permission

---

Abstract

The emergence of drug-resistant tuberculosis is a major threat to tuberculosis care and control throughout the world. The lack of effective, affordable and safe drugs for the treatment of MDR-TB is a key factor in the inability of programs to boost up their treatment efforts to meet national and global targets. Delamanid, a newer mycobacterial cell wall synthesis inhibiting drug, received a conditional approval from European medicines agency for the treatment of MDR-TB. Delamanid, in addition to its previously demonstrated efficacy in pulmonary tuberculosis, might be an effective therapeutic approach to treating extra pulmonary tuberculosis. Treatment with Delamanid for 6 months in combination with an optimized regimen can improve patient outcomes and reduce mortality and morbidity among patients with both multidrug-resistant (MDR) and extensively drug-resistant TB (XDR).

Keywords: Delamanid; Efficacy; MDR-TB; Tuberculosis

How to cite : Atif M, Maroof M, Yadav S, Delamanid- A ray of hope for drug resistant tuberculosis. IP Indian J Immunol Respir Med 2017;2(3):66-68

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.